You are here: Home > News > Press Releases

PRESS RELEASES

IXICO Closes Operational & Technology Investment Financing

London, England, December, 2010

IXICO, Ltd., a global provider of clinical trial image management and imaging informatics technologies announced the closing of a £1m private financing round. The investment from existing shareholders was led by Imperial Innovations and The Capital Fund with strong participation from the rest of its shareholder base and will support the company's continued operational expansion and the further commercialization of its world leading image management technologies. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Appoints Jessica Payne as Sales Manager, New Accounts

London, England, 21 May, 2010

IXICO, Ltd., a global provider of clinical trial image management services and technologies, announced today that it has hired Jessica Payne as Sales Manager, New Accounts, to support the company’s continued sales growth. Payne joins IXICO as part of the company’s continued efforts to identify new therapeutic areas where the company’s core strengths provide a competitive advantage, and to develop active leads in those areas. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Hires US-based Senior Project Manager

London, England, 5 May, 2010

IXICO, Ltd., announced today that it has hired Karen Graham, RN, of Chicago, IL as its first US-based Senior Project Manager. Graham joins IXICO as part of the company’s continued US growth in reflection of its increase in US-based business and global Phase II and Phase III studies. Graham comes to IXICO as part of a career in regulatory submissions, site management, and project management across a wide range of therapeutic areas and clinical trial phases. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Awarded Phase II Alzheimer’s Disease Study

London, England, 29 April, 2010

IXICO, Ltd., a global imaging CRO, announced today that a leading pharmaceutical company has awarded IXICO a Phase II clinical imaging study to evaluate the safety and efficacy of their Alzheimer’s Disease (AD) therapy with magnetic resonance imaging (MRI). IXICO will provide clinical study management and full imaging services, including protocol consultation, site management (site evaluation, qualification, training, and communications), image handling (data transfer and storage via IXICO’s TrialTracker™ Image Management System), image data QC, real-time reporting, imaging charter development, and analysis of MR images for safety and brain atrophy using a variety of endpoints. The study will commence in autumn 2010, recruiting more than 600 patients at over 60 sites across a four year period. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Commences work on Phase III Liver Cancer Study

London, England, 13 April, 2010

IXICO, Ltd., a global imaging CRO, announced today that it has commenced work with a leading academic institution running the imaging component of a Phase III study. IXICO will provide clinical study management and full imaging services. The study will assess the efficacy of a proprietary drug in combination with transcatheter arterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC) using the response evaluation criteria in solid tumours (RECIST). RECIST is the accepted standard for measuring tumor response to therapeutic intervention, using X-ray, CT, or MR images. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Surpasses Sales Target for 2009-2010 Fiscal Year

London, England - 24 March, 2010

IXICO, Ltd., a global provider of clinical trial image management services and technologies, announced today that it has exceeded its annual sales target by twenty-five percent (25%), three months before the end of its fiscal year. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Promotes John Hall, Ph.D., to Director, Business Development

London, England - 24 March, 2010

IXICO, Ltd., a global provider of clinical trial image management services and technologies, announced today that it has promoted John Hall, Ph.D. to Director, Business Development in reflection of his growing achievements and managerial responsibilities. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO is Awarded Pilot Study from a Global Pharmaceutical Company for its TrialTracker™ Image Management System

London, England - 18 March, 2010

------------------------------------------------------------------------------------------------------

IXICO’s CEO, Derek Hill to Participate in the Coalition Against Major Diseases (CAMD) Consortium

London, England – 28 January, 2010

The initial goal of CAMD is to define clinical data standards and establish a pooled database of the control groups of pharmaceutical clinical trials in order to develop quantitative disease progression models for both Alzheimer's and Parkinson's diseases. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO Appoints Andy Richards as Chairman to initiate next phase of growth

London, England – 22 September, 2009

IXICO is delighted to announce that on 2^nd September, Dr. Andy Richards joined the board as Chairman. Dr Richards is an established bio-science entrepreneur who has been instrumental in the founding or growth of several successful and innovative Healthcare companies including Chiroscience, Arakis, Cambridge Biotechnology, Altacor and Vectura. He has a track record in transforming companies from science based start ups to commercial ventures that raise funds and achieve successful exits. He has wide experience of commercialisation partnerships, M&A transactions and of private and public market financings. Click here to read in full.

------------------------------------------------------------------------------------------------------

IXICO, Ltd. Announces Formation of US Operation in Chicago, Illinois

London, England - 11 May, 2009

------------------------------------------------------------------------------------------------------

IXICO launches TrialWire™, a free, web-based tool for de-identifying, organizing, and moving medical image data

London, England

Today, at the ISMRM conference in Hawaii, IXICO has released a free medical image management tool, TrialWire™. TrialWire™ is a web-based tool for de-identifying, organizing, and electronically transferring medical images in the global standard DICOM format. Developed by IXICO's team of in-house medical imaging experts to maximize speed and efficiency of image data management, TrialWire's™ unique technology is already being used for handling image data collected at many dozens of sites around the world. IXICO is now making TrialWire™ available to anyone interested in medical image data management, whether they are involved in imaging-based clinical trials, research, or simply need a tool for efficient image data management. Click here to read in full.

------------------------------------------------------------------------------------------------------

PRESS RELEASES - in full

IXICO Closes Operational & Technology Investment Financing

London, England, December, 2010 – IXICO, Ltd., a global provider of clinical trial image management and imaging informatics technologies announced the closing of a £1m private financing round. The investment from existing shareholders was led by Imperial Innovations and The Capital Fund with strong participation from the rest of its shareholder base and will support the company's continued operational expansion and the further commercialization of its world leading image management technologies.

"The year to 31 May 2010 was our best year ever in clinical trials services, and such success justifies our growth strategy. With our additional financing, we will be able to build on our leading position in neurodegeneration imaging trials and enhance our capability in the oncology space. This will also all us accelerate the deployment of our TrialTracker™ Image Management System in the academic, healthcare and commercial environments," said IXICO's founder and CEO, Derek Hill, PhD. "This is a significant achievement and it caps a fantastic year for us at IXICO."

Maina Bhaman from Imperial Innovations said “IXICO is an excellent example of how technology can be applied to the healthcare arena, which, along with its strong revenue growth and blue chip pharmaceutical customer base, makes this a compelling investment proposition.”

"Such strong support from our existing shareholder base has been most gratifying and will allow continued investment in our technology, our commercial infrastructure, and in new partnerships to optimize the impact of our technologies in clinical research. " said Andy Richards, IXICO's Chairman. “Imaging has become a critical yet challenging element of clinical research and I look forward to working with Derek and the team to realize the major corporate opportunity that this provides."

About IXICO

IXICO, Ltd. is a full-service Imaging CRO that provides comprehensive, technology-based solutions for the pharmaceutical and biotech industries across all therapeutic areas and clinical trials phases. IXICO has designed its systems to address the critical areas of imaging based clinical trials from data acquisition to analysis and has developed a suite of software-based tools – including its TrialWire™ electronic data transfer portal and its TrialTracker™ Image Management System – to optimize imaging trial workflows.

For more information please contact: John Hall, VP of Business Development at John.hall@ixico.com

IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street,

London NW1 0NH England - www.ixico.com

---------------------------------------------------------------------------------------------------------------------

IXICO Appoints Jessica Payne as Sales Manager, New Accounts

London, England, 21 May, 2010 – IXICO, Ltd., a global provider of clinical trial image management services and technologies, announced today that it has hired Jessica Payne as Sales Manager, New Accounts, to support the company’s continued sales growth.

“We are thrilled to welcome Jessica to our Business Development Team,” said John Hall, Director of Business Development. “Jessica brings a solid bioscience background and practical experience developing customer relationships and new market opportunities. As Sales Manager, Jessica will provide sales support to the existing business development team as well as managing a number of defined accounts and generating new opportunities with pharmaceutical and biotechnology companies.”

Payne joins IXICO as part of the company’s continued efforts to identify new therapeutic areas where the company’s core strengths provide a competitive advantage, and to develop active leads in those areas.

Before joining IXICO, Payne was Sales and Marketing Executive at Gold Key Media, one of the largest distributors of newspapers, magazines and targeted media to companies throughout Europe and Asia. At Gold Key Media, Jessica was instrumental in growing a new arm of their business, developing the customer base and product offerings, and managing both key accounts and supplier relationships.

“I’m delighted to be appointed at such an exciting time,” said Payne. “I look forward to working with IXICO and ensuring continuous sales growth”

About IXICO

For more information please contact: John Hall, Director of Business Development at john.hall@ixico.com

IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street,

London NW1 0NH England - www.ixico.com

-----------------------------------------------------------------------------------------------------------

IXICO Hires US-based Senior Project Manager

London, England, 5 May, 2010

IXICO, Ltd., a global imaging CRO providing of clinical trial image management services and technologies, announced today that it has hired Karen Graham, RN, of Chicago, IL as its first US-based Senior Project Manager.

“We’re pleased to announce that Karen Graham has joined our team,” said Derek Hill, CEO. “Karen brings with her a track record of excellence and a wealth of experience in clinical trials project management. She brings not only the capability to oversee the complexities of effective communication between IXICO, trial sponsors, and the large number of imaging sites we engage, but also a keen understanding of the entrepreneurial spirit needed to continue our pioneering approach to image management. We look forward to working with Karen and we know that she’ll be a great asset to us as we continue to grow.”

Graham joins IXICO as part of the company’s continued US growth in reflection of its increase in US-based business and global Phase II and Phase III studies. Graham comes to IXICO as part of a career in regulatory submissions, site management, and project management across a wide range of therapeutic areas and clinical trial phases. Before joining IXICO, Graham was the co-founder and administrator of a Site Management Organization (SMO) and Institutional Review Board in Petoskey, Michigan, which she ran for ten years before selling the business. Following that success, Graham spent the next ten years as an Administrative Consultant for a multi-disciplinary clinical trials program in Petoskey, Michigan before working as a Clinical Development Specialist for NMT Medical of Boston, MA, a Heart Failure Clinical Specialist for Bioventrix of Danville, CA, and as a Clinical Science Liaison for Spiration, Inc., of Redmond, Washington.

“I’m very pleased to become a part of this talented and exciting team,” said Graham. “I look forward to bringing both my site-based and industry project management skills and experiences to contribute to the overall success of the company.”

About IXICO

For more information please contact: Ciaran Cooper, VP Business Development at ciaran.cooper@ixico.com

IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH England - www.ixico.com

------------------------------------------------------------------------------------------------------------

IXICO Awarded Phase II Alzheimer’s Disease Study

London, England, 29 April, 2010

IXICO will provide clinical study management and full imaging services, including protocol consultation, site management (site evaluation, qualification, training, and communications), image handling (data transfer and storage via IXICO’s TrialTracker™ Image Management System), image data QC, real-time reporting, imaging charter development, and analysis of MR images for safety and brain atrophy using a variety of endpoints. The study will commence in autumn 2010, recruiting more than 600 patients at over 60 sites across a four year period.

“This award follows on the heels of our previous success in supporting this sponsor and we are thrilled to take this on as it dovetails nicely with our ongoing efforts on their behalf,” said Ciaran Cooper, IXICO’s Vice President of Business Development. “This trial further demonstrates our proven abilities in neurodegeneration studies across all clinical trial phases. We have a tremendous track record in AD trials using various modalities, biomarkers, and endpoints, including volumetric MRI assessments of statins, gamma-secretase modulators, and passive immunotherapy monoclonal antibodies.”

“We’re very pleased with this award,” said John Hall, PhD, Director of Business Development. “The integration of our TrialTracker™ Image Management System with our internal workflows and core expertise in Alzheimer’s Disease allows us to provide an imaging solution unmatched in the industry. We look forward to the successful completion of this study and to our continuing support of this sponsor’s AD program.”

About IXICO

For more information please contact: Ciaran Cooper, VP Business Development at ciaran.cooper@ixico.com

IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street,

London NW1 0NH England - www.ixico.com

--------------------------------------------------------------------------------------------------------------

IXICO Awarded Phase III Liver Cancer Study

London, England, 13 April, 2010

IXICO, Ltd., a global imaging CRO, announced today that a leading academic institution has awarded IXICO a Phase III clinical imaging study. IXICO will provide clinical study management and full imaging services. The study will assess the efficacy of a proprietary drug in combination with transcatheter arterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC) using the response evaluation criteria in solid tumours (RECIST). RECIST is the accepted standard for measuring tumor response to therapeutic intervention, using X-ray, CT, or MR images.

The study will commence in spring 2010, recruiting more than 400 patients at dozens of sites, over a three year period. IXICO will provide protocol consultation, site management (site evaluation, qualification, training and communications), image handling (data transfer and storage via IXICO’s TrialTracker™ Image Management System), real-time image data QC, reporting, and analysis of CT and MR images using RECIST. The award of this liver cancer study demonstrates IXICO’s growing backlog of RECIST studies based on our core therapeutic area strengths specifically in oncology and neurodegeneration.

“The award of this Phase III, oncology study demonstrates that our customers recognize the value of IXICO’s innovative imaging solutions, which provide higher image quality and shorter timelines” notes Derek Hill, CEO. “Our solution combines the latest release of our image management technology with rigorous application of well established radiological endpoints to provide the study flexibility that the investigators require”.

About IXICO

For more information please contact: Erin Coberth, Contracts & Proposals Manager at erin.coberth@ixico.com

-------------------------------------------------------------------------------------------------------

IXICO Surpasses Sales Target for 2009-2010 Fiscal Year

London, England - 24 March, 2010

The increase in IXICO’s image management business is attributed to its expansion into new therapeutic areas and late phase trials based on a solid track record of performance on prior early phase trials. In addition, IXICO has seen a notable increase in Phase II and III awards in its core areas of strength in neurodegeneration and oncology.

“We’re thrilled to announce that we’ve already exceeded our sales target for this fiscal year,” notes Ciaran Cooper, Vice President of Business Development, “and we’ve still got three more months before our year end. We’ve built a solid foundation from which we’re primed to grow our business over the next several years. Our key areas of focus are to continue growing our core strengths in oncology and neurodegeneration, most notably Alzheimer’s disease, while we parlay our successes into new opportunities and market niches. In addition, we will continue to integrate into our services our enabling image management technologies, which provide tremendous value to our customers and make us stand out among our competitors. It’s an exciting year.”

IXICO’s image management services are centered on the recognition that the most critical aspects of success lay in providing a seamless and comprehensive approach to the entire imaging trial spectrum, not solely the imaging core lab piece post-acquisition and pre-analysis. By design, IXICO has built its systems and workflows to address the critical areas of data acquisition, transfer, management, and analysis, including protocol optimization, site training, scanner QA, real-time data QC, and leading analysis methods. IXICO has developed a suite of enabling technology-based tools to help optimize this continuum, including its TrialWire™ electronic data transfer tool, its TrialTracker™ image management system, and its QCWizard™ semi-automated QC workflow.

About IXICO

For more information please contact: Ciaran Cooper, VP Business Development at ciaran.cooper@ixico.com

-------------------------------------------------------------------------------------------------

IXICO Promotes John Hall, Ph.D., to Director, Business Development

London, England - 24 March, 2010

“John continues to be one of our key employees and top performers,” said Ciaran Cooper, Vice President, Business Development. “John’s constant enthusiasm and hard work on behalf of our company and clients is a major asset to IXICO. John’s efforts have also played a significant role in our surpassing our sales targets for this fiscal year. In addition to his own sales responsibilities, he has happily taken on an increasing amount of managerial responsibilities, and this promotion reflects not only our reliance on his hard work but also our desire to see him continue to flourish and grow as we do.”

Hall joined IXICO in May 2008 as Manager, Business Development, and has overseen several key accounts while also helping streamline IXICO’s growing business development efforts into new market niches and product lines. Hall holds his Ph.D. in proteomics from The University of Durham and has successfully adapted his strong scientific background to the complexities and rigor of the medical imaging arena. Hall recently completed the Dale Carnegie LTM Management Training Program and was awarded the Leadership Award in recognition by his peers of his growth over the duration of the course.

“I’m very pleased to receive this promotion and to have been given the opportunity to attend the LTM program,” said Hall. “I look forward to applying what I learned in the program to help us achieve even higher goals as we continue along our path of success.”

About IXICO

For more information please contact: Ciaran Cooper, VP Business Development at ciaran.cooper@ixico.com

----------------------------------------------------------------------------------------------------

IXICO is Awarded Pilot Study from a Global Pharmaceutical Company for its TrialTracker™ Image Management System

London, England - 18 March, 2010

IXICO, Ltd., a global provider of clinical trial image management services and technologies, announced today that it has been awarded its first commercial pilot from a global pharmaceutical company for its TrialTracker™ Image Management System (IMS). TrialTracker™ is IXICO’s web-based tool for comprehensive management of all imaging data from acquisition to analysis.

TrialTracker™ provides real-time tracking of critical imaging trial information such as timepoint completion, open queries, and analysis status, on a site or subject level. It can hold information from multiple studies for cross-trial comparisons and meta-analyses. TrialTracker™operates through a central database with a web-based interface for upload and download of data with real-time status updates.

Because TrialTracker™ is a web-based tool with role-based access, it can provide trial data to different members of a study team from anywhere in the world, which makes it an invaluable tool for today’s evolving global trials. TrialTracker™ is IXICO’s leading technology-based tool for image and project management. It has the potential to revolutionize imaging trial management and reporting and to have a major impact on the cost, efficiency, and quality of image data collected in clinical trials.

“The success of an imaging trial depends heavily on the project team’s ability to accurately track progress and to see the data as it is collected to ensure that good quality data is being acquired,” said Derek Hill, Ph.D., IXICO’s founding CEO. “We are very pleased to conduct this pilot study with our global pharmaceutical partner to test it under various real-world scenarios. We have been using earlier versions of TrialTracker™ internally for the past several years to manage trials for which we were contracted to provide complete ICRO services, but this pilot represents our first commercial application of TrialTracker™ as a free-standing image management tool. This pilot is also one of several pilots planned or underway with academic partners and other commercial partners. It is an exciting time for us as we continue to look for innovative ways to apply our enabling technologies to the issues facing clinical trials today.”

About IXICO
IXICO, Ltd. is a full-service Imaging CRO that provides comprehensive, technology-based solutions for the pharmaceutical and biotech industries across all therapeutic areas and clinical trials phases. IXICO works within an ISO9001:2008 certified Quality Management System.
For more information please contact: Neil Strange, Product Manager at neil.strange@ixico.com
IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street,
London NW1 0NH England - www.ixico.com
© 2010 IXICO, Ltd. All rights reserved

------------------------------------------------------------------------------------------------------

IXICO’s CEO, Derek Hill to Participate in the Coalition Against Major Diseases (CAMD) Consortium

London, England – 28 January, 2010

IXICO, Ltd. announced today that Derek Hill, PhD, its CEO, has been invited to participate in the Coalition Against Major Diseases (CAMD) Consortium, founded by the Critical Path Institute (C-Path), in collaboration with the Engelberg Center for Health Care Reform at the Brookings Institution. As a participant, Prof. Hill will help the Consortium achieve its goals in better understanding and defining the devastating effects of neurodegenerative diseases.

The initial goal of CAMD is to define clinical data standards and establish a pooled database of the control groups of pharmaceutical clinical trials in order to develop quantitative disease progression models for both Alzheimer's and Parkinson's diseases.

The CAMD brings together major pharmaceutical companies, the US Food and Drug Administration (FDA), the European Medicine Agency (EMEA), the National Institute on Aging (NIA), the National Institute of Neurological Disorders and Stroke (NINDS), and patient groups in a collaboration to develop new knowledge that will enhance the medical product industry’s ability to develop innovative new therapies. The objective is to establish CAMD as a neutral ground where the regulatory agencies (FDA, EMEA), pharmaceutical industry (16 members so far), patient advocacy groups, and government agencies (NINDS and NIA) can come together to discuss the science with the aim of packaging it in a form that is actionable by the regulatory agencies. The members are the stakeholders in the therapeutics enterprise and the output from CAMD is reflective of both the science and the needs of the industry.

The Consortium has the specific aims of:
* Developing an integrated database of aggregated control group trial data in standardized format;
* To submit biomarkers to the FDA for possible qualification;
* To submit quantitative models of disease progression to the FDA for possible qualification.

CAMD members will collaborate to gather and submit the evidence necessary for the FDA and EMEA to officially designate such tools as "qualified for use" in drug development. These newly qualified tools will be made publicly available for use by scientists and commercial developers alike.

The CAMD Consortium is split into four Workgroups: Alzheimer’s Disease (AD) Biomarkers Evaluation, Data, Disease Progression Modeling, and Health Authorities Submissions.

Prof. Hill will take part in the AD Biomarkers Evaluation Workgroup, which aims to establish a process and execute a plan for compiling and evaluating the scientific merit of reported biomarkers (including imaging data) that are potentially useful in drug or diagnostic test development. Specific objectives are to:

* Establish a process for collating a comprehensive list of potential biomarkers using publicly available data and CAMD members’ proprietary data;
* Establish an evidence-based process incorporating current methods to assess scientific strength of candidate biomarkers;
* Determine which biomarkers should have priority for further development efforts, as well as specific use contacts;
* Determine when biomarkers have sufficient evidence to be submitted to the biomarker qualification process with FDA and EMEA;
* Integrate biomarker data into quantitative disease-progression models and use evolving disease models to help with the evaluation of biomarkers.

CAMD participants include the following:
* Abbott
* Alliance for Aging Research
* Alzheimer's Association
* Alzheimer's Foundation of America
* AstraZeneca Pharmaceuticals LP
* Bristol-Myers Squibb Company
* Daiichi Sankyo
* Eli Lilly and Company
* Forest Research Institute
* Genentech Inc.
* GlaxoSmithKline
* Johnson & Johnson
* National Health Council
* Novartis Pharmaceutical Corporation
* Parkinson's Action Network
* Parkinson's Disease Foundation
* Pfizer, Inc.
* Roche
* Sanofi-Aventis, US, Inc.
* Schering-Plough
* Wyeth Pharmaceuticals, Inc.

About Critical Path Institute
C-Path is an independent, non-profit organization uniquely dedicated to implementing the FDA's Critical Path Initiative by creating collaborations among regulators (scientists from the FDA) and the regulated (medical product industry) that result in accelerated development of safe, new medical products.
About IXICO
IXICO offers a full range of Imaging CRO services including comprehensive, technology-based solutions for the pharmaceutical, biotech and medical device industries across all therapeutic areas and clinical trial phases. IXICO recently released TrialWire™, its free, web-based image management tool. IXICO works within an ISO 9001:2008 certified Quality Management System.

For more information please contact: Erin Coberth, Contracts & Proposals Manager at erin.coberth@ixico.com or by phone +44 207 691 2064
Company address: The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH England - www.ixico.com
© 2010 IXICO LTD. All rights reserved
------------------------------------------------------------------------------------------------------

IXICO Appoints Andy Richards as Chairman to initiate next phase of growth

London, England - 22 September, 2009

IXICO is delighted to announce that on 2nd September, Dr. Andy Richards joined the board as Chairman. Dr Richards is an established bio-science entrepreneur who has been instrumental in the founding or growth of several successful and innovative Healthcare companies including Chiroscience, Arakis, Cambridge Biotechnology, Altacor and Vectura. He has a track record in transforming companies from science based start ups to commercial ventures that raise funds and achieve successful exits. He has wide experience of commercialisation partnerships, M&A transactions and of private and public market financings.

Dr Richards will be joining the Board of IXICO to help steer it through its next phase of growth as it expands its Imaging CRO services business and prepares to launch a new series of technology products that will transform the way that medical images are managed throughout the healthcare sector. IXICO’s technology products include Trial WireTM-free, which was launched in April as a tool for sharing de-identifying and organization of medical image data for research purposes, and TrialTracker™, being launched this month, our next-generation image management solution that enables trial sponsors to track and control their data. Both products will be demonstrated at MICCAI, London and WMIC, Montreal in September.

In addition to his role on IXICO’s board, Dr Richards holds other non-executive director positions including Vectura group plc, Summit Corp plc, Altacor, Biowisdom, Babraham Bioscience Technology and Cancer Research Technology (the commercial arm of CR-UK). He is a director of the UK Bio-industry Association and was recently voted both Cambridge Evening News Businessman of the Year and one of the Top100 Living Contributors to Biotechnology.

Derek Hill, IXICO’s CEO said “We are very excited that Andy has joined our board. His enthusiasm, energy and experience will be invaluable as we take our business forward and explore the many opportunities available to us to enhance the way imaging is used in clinical trials, and explore new avenues for our technology.”

Andy Richards commented “IXICO is an exciting and entrepreneurial healthcare information technology (HCIT) business. The solid commercial platform it has built in CRO services along with its transformational new technologies provide real opportunities for growth. I have been impressed with what Derek and his team have achieved to date and I look forward to help make IXICO an international commercial success”

About IXICO
IXICO is dedicated to improving the field of medical imaging through superior service and enabling technologies that support basic imaging research, routine clinical imaging, and imaging-based clinical trials. In its capacity as a full-service Imaging CRO, the company's Trial Service Division provides comprehensive, technology-based solutions and novel imaging biomarkers for the pharmaceutical and biotech industries across all therapeutic areas and clinical trials phases; from expert acquisition design and imaging site management to image QC and proven analysis techniques, IXICO’s workflow technology and imaging know-how is driven by highly qualified and experienced experts and is underpinned by our robust quality management system. The company's New Product Division provides software solutions for image data management: improved regulatory-compliant image workflows, more efficient project management, data re-use; aggregation of data from multiple studies, and easier sharing and communication of images. To learn more about IXICO's service and product offerings, please visit www.ixico.com

------------------------------------------------------------------------------------------------------

IXICO, Ltd. Announces Formation of US Operation in Chicago, Illinois

London, England - 11 May, 2009

IXICO, Ltd., a global imaging technology and service company, announced today that it has opened its US operations in Chicago, Illinois. The new entity, formally known as IXICO US LLC, is owned in entirety by IXICO, Ltd., of London, England.

IXICO’s US office will provide business development and project management support to its expanding US customer base. The US office will also help facilitate IXICO’s planned expansion of its imaging center network and partnership alliance.

“We are very excited to extend our functional capabilities across the Atlantic, and Chicago provides a perfect central location to support our customers on both coasts,” said Derek Hill, Ph.D., IXICO’s founding CEO. “Chicago also provides a rich environment of imaging expertise at its local universities, as well as a pool of highly educated, well trained professionals in clinical trials project management.”

IXICO US will be managed by Ciaran Mark Cooper, Vice President US Business Development. “Our extended operational footprint is the perfect complement to our expanding business core,” said Cooper. “In addition to our full-service ICRO capabilities, we have recently released several new web-based image management tools that offer terrific value to our customers, both large and small. These tools can help optimize the communication and image management in the execution of imaging trials while providing significant time and cost savings to our clients. Our US expansion is a further indication of our growing business and continuing success.”

About IXICO
IXICO offers a full range of Imaging CRO services including comprehensive, technology-based solutions for the pharmaceutical, biotech and medical device industries across all therapeutic areas and clinical trial phases. IXICO recently released Trial Wire, its free, web-based image management tool. IXICO works within an ISO 9001:2008 certified Quality Management System.

For more information please contact: Kranti Parekh, Marketing Manager at kranti.parekh@ixico.com or by phone 0044 207 6913564
Company address: The London Bioscience Innovation Centre, 2 Royal College Street,
London NW1 0NH England - www.ixico.com
© 2009 IXICO LTD. All rights reserved

IXICO launches Trial Wire, a free, web-based tool for de-identifying, organizing, and moving medical image data

London, England

Today, at the ISMRM conference in Hawaii, IXICO has released a free medical image management tool, Trial Wire. Trial Wire is a web-based tool for de-identifying, organizing, and electronically transferring medical images in the global standard DICOM format. Developed by IXICO's team of in-house medical imaging experts to maximize speed and efficiency of image data management, Trial Wire's unique technology is already being used for handling image data collected at many dozens of sites around the world. IXICO is now making Trial Wire available to anyone interested in medical image data management, whether they are involved in imaging-based clinical trials, research, or simply need a tool for efficient image data management.

Trial Wire 2.0 beta allows users to easily de-identify image data to help maintain compliance with global patient privacy regulations, including HIPPA and the EU Directive on the Protection of Personal Data. The tool also allows users to organize image data into DICOM hierarchical structures and then transfer the data securely over the internet. As a bonus feature, Trial Wire provides a complete audit trail (a record of everything done to the data and by whom it was done), which can be saved electronically or printed and filed. Whether users need to sort through and organize archived image data or securely transfer de-identified data to a CRO or clinical trial sponsor (or simply from a hospital to an adjacent research lab), Trial Wire can be accessed from any web-enabled computer.

"Medical imaging is very widely used for clinical trials and research", said Derek Hill, CEO of IXICO. "However, it is currently a huge amount of effort to handle this data in a way that preserves patient privacy and organizes the data in a way that is easy to use. We wanted to offer a product that addresses the most basic issues of image data management, and make it freely available", said Derek Hill, CEO of IXICO. "By providing de-identification, organization, and transfer in an easy-to-use web-based tool, we believe we can help the entire imaging research community improve its efficiency while ensuring that patient privacy is protected. We believe that the best way to make a positive impact on these issues is to foster the widespread adoption of a single, easy-to-use, web-based tool. No one should have to pay for image data transfer any more than they should have to pay to send an email or other file over the internet. In addition to the secure transfer function, we felt that it was important for users to also be able to organize and de-identify the data through the same tool. Our hope is that with the adoption of Trial Wire throughout the medical imaging world, we'll help our colleagues around the globe solve the most basic set of problems facing us today while also leading the way to greater innovation in other, more complex areas."

The easy-to-use interface is based on a series of pull-down menus and user prompts, which can be customized to user-specific, or trial-specific requirements. Trial Wire is now available online with the following features enabled:

1. Quick and simple setup - Using a simple web-based Java applet, Trial Wire requires no installation or hardware set-up and no dedicated computer. Simply register online for free, and within minutes you can begin to enjoy the benefits.

2 Easy de-identification - Set up the parameters for your trial and save your settings. De-identify standard tags and additionally ask Trial Wire to search for other potentially identifiable tags to alert you to.

3. Logical sort and structure - Read DICOM files from any directory and sort into Subject, Study, Series hierarchy. Output this new structure locally or transfer elsewhere.

4. Secure DICOM transfer with audit trail - Configure Trial Wire to transfer data to your secure FTP server after de-identification and organization. Print off the audit trail report for inclusion in the study folder.

The IXICO team will be demonstrating Trial Wire at ISMRM in Honolulu. Visit them at booth 322 to register for Trial Wire and receive a free gift. Or register for your free Trial Wire account today! To find out more, visit www.mytrialwire.com.